ResMed Officer & Director Michael J. Farrell Files Form 144 to Sell $1.13M Under 10b5-1 Plan

Executive Summary

On October 7, 2026, Michael J. Farrell, Officer and Director of ResMed Inc. ($RMD), submitted a Form 144 filing declaring the intention to sell 4,991 shares of common stock with an aggregate market value of approximately $1.13 million.

Transaction Details

• Security: Common Stock
• Volume: 4,991 shares
• Estimated Price per Share: ~$226.34
• Total Proposed Proceeds: $1,129,637.70
• Acquisition Nature: Acquired on October 7, 2026, via stock option exercise from the issuer paid in cash.
• Trading Plan: Executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024.
• Broker: Fidelity Brokerage Services LLC

Historical Context & Prior Sales

The filing reflects regular, scheduled sales of 4,991 shares per month over the prior three months:

• September 8, 2026: 4,991 shares sold for $1,110,190.55
• August 7, 2026: 4,991 shares sold for $1,026,596.29
• July 7, 2026: 4,991 shares sold for $1,090,770.57

Significance & Market Impact

Trading significance is rated Low. The transaction represents a routine, programmatic exercise and sale under an established Rule 10b5-1 plan. Relative to ResMed's 144,252,306 outstanding shares, the proposed sale of 4,991 shares accounts for approximately 0.003% of total common stock, presenting minimal market impact.